日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?

医疗合并症和治疗方面的差异是否会影响上皮性卵巢癌的种族差异?

Dilley, Sarah; Erickson, Britt K; Phillips, Caroline E; Kennemer, Caroline R; Zhang, Bin; Matin, Tasnia; Martin, Jovana Y; Shah, Monjri M; Michael Straughn, J Jr; Leath, Charles A 3rd

Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement project

标准化的术前临床数据算法能否改善卵巢癌患者的预后?一项质量改进项目

Shah, Monjri M; Leath, Charles A 3rd; Daily, Laura Rebecca; McGwin, Gerald Jr; Estes, Jacob M; Alvarez, Ronald D; Straughn, John Michael Jr

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer

利用患者来源的异种移植模型的异质性来识别卵巢癌中的化学耐药人群

Zachary C Dobbin, Ashwini A Katre, Adam D Steg, Britt K Erickson, Monjri M Shah, Ronald D Alvarez, Michael G Conner, David Schneider, Dongquan Chen, Charles N Landen

Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer

Endoglin (CD105) 导致铂类耐药,是上皮性卵巢癌肿瘤特异性治疗的靶点

Angela J Ziebarth, Somaira Nowsheen, Adam D Steg, Monjri M Shah, Ashwini A Katre, Zachary C Dobbin, Hee-Dong Han, Gabriel Lopez-Berestein, Anil K Sood, Michael Conner, Eddy S Yang, Charles N Landen

Smoothened antagonists reverse taxane resistance in ovarian cancer

平滑拮抗剂可逆转卵巢癌的紫杉烷耐药性

Adam D Steg, Ashwini A Katre, Kerri S Bevis, Angela Ziebarth, Zachary C Dobbin, Monjri M Shah, Ronald D Alvarez, Charles N Landen